ข่าวประชาสัมพันธ์ Lung+Cancer+vandetanib

Ministry of Public Health Unites All Sectors to Advance Lung Health in Thailand

The Department of Medical Services, Ministry of Public Health, has joined forces with all parties to advance Thailand's lung health agenda through the "Lung Health Policy Forum: Breathing Matters A Policy Vision for Stronger Lung Health for Thai People". The forum aims to accelerate action on lung cancer and chronic obstructive pulmonary disease (COPD), while promoting equitable access to innovative screening and treatment from the earliest stages of disease. The initiative seeks to sustainably

24 กรกฎาคม 2569 17:49 น.

สธ. จับมือทุกภาคส่วน เดินหน้าเวทีนโยบายสุขภาพปอด เร่งรับมือมะเร็งปอด-โรคปอดเรื้อรัง ลดความเหลื่อมล้ำการเข้าถึงการรักษา — กรมการแพทย์ กระทรวงสาธารณสุข ผนึก... 24 ก.ค.

Happy Chemo Club by Nutrepreme ร่วมกับ Art for Cancer by Ireal จัดกิจกรรม "The Gentle Gut Balance Experience" — "สุขภาพลำไส้" กำลังกลายเป็นอีกหนึ่งประเด็น... 26 พ.ค.

CAPRELSA(TM) (vandetanib) Receives Positive CHMP Opinion in the European Union for Treating Advanced Medullary Thyroid Cancer

AstraZeneca today announced that the Marketing Authorisation Application for CAPRELSA (vandetanib) received a positive opinion from the Committee for Medicinal Products for... พ.ย. 54

Vandetanib Phase II Trial Shows Significant Improvement of Progression Free Survival in Patients With Advanced Papillary or Follicular Thyroid Cancer

- This press release has been made available on worldwide (excluding US) press communication media for the benefit of correspondents writing for the... ก.ย. 53

Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology

Data from the Phase III ZODIAC(1) study in advanced non-small cell lung cancer patients, with the investigational drug vandetanib, were... มิ.ย. 52

Fourth Phase III Study of Vandetanib (ZACTIMA(TM), ZD6474) in Patients With Advanced Lung Cancer

A Phase III international, parallel group, randomised, double-blind study of vandetanib in combination with pemetrexed for advanced non-small cell lung cancer (NSCLC) after failure of first line anti... ก.พ. 50